Vyjuvek

Vyjuvek (beremagene geperpavec) is a topical gene therapy for skin wounds, designed to support healing in certain conditions. This EU-approved treatment targets chronic wounds by delivering active proteins directly to affected areas. Ideal for patients seeking advanced wound care options. Suitable for cutaneous use only.

Vyjuvek is used to treat chronic wounds, particularly diabetic foot ulcers and other non-healing skin injuries. It works by delivering functional genes to the wound site, promoting natural healing processes. Patients with persistent wounds may benefit from this targeted approach. Always consult a healthcare provider to determine suitability.

When applied as directed, Vyjuvek supports the body’s natural wound-healing mechanisms by encouraging cell growth and repair. Users may notice gradual improvement in wound size and closure over time. The treatment is designed for cutaneous application and is not intended for internal use. Results vary by individual condition.

Vyjuvek should only be handled by trained professionals in a clinical setting. Avoid contact with eyes or mucous membranes during application. Store the product according to manufacturer guidelines to maintain efficacy. Patients should follow all post-treatment care instructions provided by their healthcare provider.

As a topical gene therapy, Vyjuvek has minimal systemic interactions. However, concurrent use of other topical medications on the same wound site may affect treatment outcomes. Always inform your healthcare provider about all medications and treatments you are using. No specific drug interactions have been widely reported.